CA 19-9 as a marker for gastrointestinal cancers: A review

Annals of Clinical Biochemistry

Volumn 35, Issue 3, 1998, Pages 364-370

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MARKER; MUCIN;

COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; HUMAN; METASTASIS; PANCREAS CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; STOMACH CANCER;

EID: 0031745038     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329803500304     Document Type: Review

References (43)

1. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fulner P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-72
2. Magnani J, Nilson B, Brockhaus M, Smith DF, Ginsburg V, Blaszcyk M. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lactoN-fucopenteose II. J Biol Chem 1982; 257: 14365-9
3. Itkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology 1986; 90: 491-6
4. Ho JJL, Kim YS. Do mucins promote tumor cell metastasis? (Review). Int J Oncol 1995; 7: 913-26
5. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-77
6. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis V, Freeman G. Breast cancer-associated antigen, DF3/MUCI, induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367-70
7. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, MaClure M. Radioimmunometric assay for a monoclonal antibody-defined tumor marker. Clin Chem 1983; 29: 549-52
8. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterology 1990; 85: 350-5
9. Duffy MJ. New cancer markers. Ann Clin Biochem 1989; 26: 379-87
10. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997 349: 485-9
11. Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersan M, Zerbi A. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92: 60-70
12. Moossa AR, Gemagami RA. Diagnosis and staging of pancreatic neoplasms. Surg Clin N Am 1995; 75: 871-90
13. Duffy MJ, O'Sullivan F, O'Donoghue D, Afdhal N, Kelleher D. CA 19-9, a new marker for gastrointestinal malicnancy. Ir J Med Sci 1985; 154: 385-6
14. Steinberg WM, Gelfand R, Anderson KK, Glen J, Kurtzman SH, Sindelar WE. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assay in detecting cancer of the pancreas. Gastroenterology 1986; 90: 343-9
15. Ritts RE, Del Villano BC, Go N, Herberman R, Klug T, Zurawski VR. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer 1984; 33: 339-45
16. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serological marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-9
17. Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta H. CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57: 1324-6
18. DelMaschio A, Vanzulli A, Sironi S, Castrucci M, Mellone R, Staudacher C. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT and CT-guided fine-needle biopsy. Radiol 1991; 178: 95-9
19. Glen J, Steinberg WM, Kurtzman SH, Sternberg SM. Evaluation of the utility of a radioimmunoassay for serum CA 9-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-8
20. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 218: 350-5
21. Gattini AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78: 57-62
22. Beastall GH, Cook B, Rustin GJS, Jennings J. A review of the role of established tumour markers. Ann Clin Biochem 1991; 28: 5-18
23. Beretta E, Malesci A, Zerbi A, Mariam A, Carbucci M, Bonato C. Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 7428-31
24. Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin J-P, Pitkanen R. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer 1984; 49: 135-9
25. Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of 4 tumor markers, CA 242, CA 19-9, TPA and CEA in carcinomas of the colon. Anticancer 1996; 16: 2325-32
26. Staab HJ, Brummendorf A, Hornung A, Anderer FA, Kieninger G. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochenschr 1985; 63: 106-15
27. Filella X, Molina R, Pique JM, Garcia-Valdecasas JC, Grau JJ, Novell F. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumor Biol 1994; 18: 1-6
28. Anonymous. Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer [Special Article]. J Clin Oncol 1996; 14: 2843-77
29. Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K. Immuno-histochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am J Gastroenterol 1994; 89: 101-5
30. Heptner G, Domschke S, Domschke W. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol 1989; 24: 745-50
31. Safi F, Berger HG, Bittner R, Buchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779-83
32. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-9
33. Fabris C, Bass O, Leandro G, Meggiato T, Elba S, Panozzo MP, et al. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer 1991; 68: 1795-8
34. Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K. Evaluation of serum pancreatic enzymes, carbohydrate antigen CA 19-9 and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 1985; 80: 630-6
35. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela D, Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197-202
36. Collazos J, Genolla J, Ruibal A. CA 19-9 in non-neoplastic liver disease. A clinical and laboratory study. Clin Chim Acta 1992; 210: 145-51
37. Duffy MJ, O'Sullivan F, McDonnell TJ, Fitzgerald MX. Increased concentration of antigen CA 19-9 in serum of cystic fibrosis patients. Clin Chem 1985; 31: 1245-6
38. Arakawa Y, Ariga H, Kano M, Matsho Y, Honda T, Morita K. Determination and clinical significance of a new carbohydrate antigen in digestive system cancers. Jpn J Med 1985; 24: 121-9
39. Craxi A, Patti C, Aragona E. Serum CA 19-9 levels in patients with hepatocellular carcinoma or cirrhosis. Ital J Gastroenterol 1985; 17: 288-9
40. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988; 33: 1223-5
41. Zucchelli GC, Pilo A, Chiesa MR, Cohen R, Bizollon CA. Growing use of non-isotopic CA 19-9 immunoassays increase between laboratory variability. Clin Chem 1995; 39: 909-11
42. Pizo A, Zucchelli GC, Cohen R, Chiesa MR, Bizollon CA. Performance of immunoassays for CA 19-9, CA 15-3 and CA 123 tumour markers evaluated from an International Quality Assessment Survey. Eur J Clin Chem Biochem 1996; 34: 145-50
43. Plebani M, Giacomini A, Beghi L, De Paoli M, Roveroni G, Galeotti F. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996; 16: 2249-52